Estimating tissue-specific TNF mRNA levels prior to anti-TNFα treatment may support therapeutic optimisation in IBD patients

References

• De Souza HSP, Fiocchi C. Immunopathogenesis of IBD: current state of the art. Nat Rev Gastroenterol Hepatol. 2016;13(1):13–27.
   PubMed Web of Science ®Google Scholar
• Gareb B, Otten AT, Frijlink HW, et al. Review: local tumor necrosis factor-α inhibition in inflammatory bowel disease. Pharmaceutics. 2020;12(6):539.
   PubMed Web of Science ®Google Scholar
• Billmeier U, Dieterich W, Neurath MF, et al. Molecular mechanism of action of anti-tumor necrosis factor antibodies in inflammatory bowel diseases. World J Gastroenterol. 2016;22(42):9300–9313.
   PubMed Web of Science ®Google Scholar
• Papamichael K, Gils A, Rutgeerts P, et al. Role for therapeutic drug monitoring during induction therapy with TNF antagonists in IBD. Inflamm Bowel Dis. 2015;21(1):182–197.
   PubMed Web of Science ®Google Scholar
• Gisbert JP, Marín AC, McNicholl AG, et al. Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed. Aliment Pharmacol Ther. 2015;41(7):613–623.
   PubMed Web of Science ®Google Scholar
• Olsen T, Goll R, Cui G, et al. Tissue levels of tumor necrosis factor-alpha correlates with grade of inflammation in untreated ulcerative colitis. Scand J Gastroenterol. 2007;42(11):1312–1320.
   PubMed Web of Science ®Google Scholar
• Olsen T, Goll R, Cui G, et al. TNF-alpha gene expression in colorectal mucosa as a predictor of remission after induction therapy with infliximab in ulcerative colitis. Cytokine. 2009;46(2):222–227.
   PubMed Web of Science ®Google Scholar
• Kennedy NA, Heap GA, Green HD, et al. Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn’s disease: a prospective, multicentre, cohort study. Lancet Gastroenterol Hepatol. 2019;4(5):341–353.
   PubMed Web of Science ®Google Scholar
• Cui G, Florholmen J, Goll R. Could mucosal TNF transcript as a biomarker candidate help optimize anti-TNF biological therapy in patients with ulcerative colitis? Front. Immunol. 2022;13:2364.
   Web of Science ®Google Scholar
• Olsen J, Gerds TA, Seidelin JB, et al. Diagnosis of ulcerative colitis before onset of inflammation by multivariate modeling of genome-wide gene expression data. Inflamm Bowel Dis. 2009;15(7):1032–1038.
   PubMed Web of Science ®Google Scholar
• Martínez-Borra J, López-Larrea C, González S, et al. High serum tumor necrosis factor-α levels are associated with lack of response to infliximab in fistulizing Crohn’s disease. Am J Gastroenterol. 2002;97(9):2350–2356.
   PubMed Web of Science ®Google Scholar
• Breese EJ, Michie CA, Nicholls SW, et al. Tumor necrosis factor α-producing cells in the intestinal mucosa of children with inflammatory bowel disease. Gastroenterology. 1994;106(6):1455–1466.
   PubMed Web of Science ®Google Scholar
• Murch SH, Braegger CP, Walker-Smith JA, et al. Location of tumour necrosis factor a by immunohistochemistry in chronic inflammatory bowel disease. Gut. 1993;34(12):1705–1709.
   PubMed Web of Science ®Google Scholar
• Tumanov AV, Grivennikov SI, Kruglov AA, et al. Cellular source and molecular form of TNF specify its distinct functions in organization of secondary lymphoid organs. Blood. 2010;116(18):3456–3464.
   PubMed Web of Science ®Google Scholar
• Jauregui-Amezaga A, Geerits A, Das Y, et al. A simplified Geboes score for ulcerative colitis. J Crohns Colitis. 2017;11:305–313.
   PubMed Web of Science ®Google Scholar
• D’Haens GR, Geboes K, Peeters M, et al. Early lesions of recurrent Crohn’s disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology. 1998;114(2):262–267.
   PubMed Web of Science ®Google Scholar
• Wang F, Flanagan J, Su N, et al. RNAscope. J Mol Diagn. 2012;14(1):22–29.
   PubMed Web of Science ®Google Scholar
• Anderson CM, Zhang B, Miller M, et al. Fully automated RNAscope in situ hybridization assays for formalin-fixed paraffin-embedded cells and tissues. J Cell Biochem. 2016;117(10):2201–2208.
   PubMed Web of Science ®Google Scholar
• Møller T, James JP, Holmstrøm K, et al. Co-detection of miR-21 and TNF-α mRNA in budding cancer cells in colorectal cancer. Int J Mol Sci. 2019;20(8):1907.
   PubMed Web of Science ®Google Scholar
• Malham M, James JP, Jakobsen C, et al. Mucosal microRNAs relate to age and severity of disease in ulcerative colitis. Aging. 2021;13(5):6359–6374.
   PubMedGoogle Scholar
• Thorlacius-Ussing G, Schnack Nielsen B, Andersen V, et al. Expression and localization of miR-21 and miR-126 in mucosal tissue from patients with inflammatory bowel disease. Inflamm Bowel Dis. 2017;23(5):739–752.
   PubMed Web of Science ®Google Scholar
• Patil I. Visualizations with statistical details: the “ggstatsplot” approach. J Open Sour Softw. 2021;6(61):3167.
   Google Scholar
• Sands BE, Chen J, Feagan BG, et al. Efficacy and safety of MEDI2070, an antibody against interleukin 23, in patients with moderate to severe Crohn’s disease: a phase 2a study. Gastroenterology. 2017;153(1):77.e6–86.e6.
   Web of Science ®Google Scholar
• Feagan BG, Sandborn WJ, D’Haens G, et al. Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn’s disease: a randomised, double-blind, placebo-controlled phase 2 study. Lancet. 2017;389(10080):1699–1709.
   PubMed Web of Science ®Google Scholar
• de Magalhães JP, Curado J, Church GM. Meta-analysis of age-related gene expression profiles identifies common signatures of aging. Bioinformatics. 2009;25(7):875–881.
   PubMed Web of Science ®Google Scholar
• Cottonham CL, Kaneko S, Xu L. miR-21 and miR-31 converge on TIAM1 to regulate migration and invasion of colon carcinoma cells. J Biol Chem. 2010;285(46):35293–35302.
   PubMed Web of Science ®Google Scholar
• Murch SH, Lamkin VA, Savage MO, et al. Serum concentrations of tumour necrosis factor in childhood chronic inflammatory bowel disease. Gut. 1991;32(8):913–917.
   PubMed Web of Science ®Google Scholar
• Yarur AJ, Jain A, Sussman DA, et al. The association of tissue anti-TNF drug levels with serological and endoscopic disease activity in inflammatory bowel disease: the ATLAS study. Gut. 2016;65(2):249–255.
   PubMed Web of Science ®Google Scholar
• Scallon B, Cai A, Solowski N, et al. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther. 2002;301(2):418–426.
   PubMed Web of Science ®Google Scholar
• Black RA, Rauch CT, Kozlosky CJ, et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature. 1997;385(6618):729–733.
   PubMed Web of Science ®Google Scholar
• Berends SE, van Steeg TJ, Ahsman MJ, et al. Tumor necrosis factor-mediated disposition of infliximab in ulcerative colitis patients. J Pharmacokinet Pharmacodyn. 2019;46(6):543–551.
   PubMed Web of Science ®Google Scholar
• Van Kruiningen HJ, Ganley LM, Freda BJ. The role of Peyer’s patches in the age-related incidence of Crohn’s disease. J Clin Gastroenterol. 1997;25(2):470–475.
   PubMed Web of Science ®Google Scholar
• Van Kruiningen HJ, Brain West A, Freda BJ, et al. Distribution of Peyer’s patches in the distal ileum. Inflamm Bowel Dis. 2002;8:180–185.
   Google Scholar
• Ruel J, Ruane D, Mehandru S, et al. IBD across the age spectrum—is it the same disease? Nat Rev Gastroenterol Hepatol. 2014;11(2):88–98.
   PubMed Web of Science ®Google Scholar